Ex vivo drug testing of patient-derived lung organoids to predict treatment responses for personalized medicine
Josephine A. Taverna(Mays Cancer Center at UT Health San Antonio), Chun‐Liang Chen(Memorial Sloan Kettering Cancer Center), Madison Williams(The University of Texas MD Anderson Cancer Center), Cheryl Hsiang-Ling Chiu(The University of Texas at San Antonio Health Science Center), Ryan A. Williams(The University of Texas MD Anderson Cancer Center), Chia‐Nung Hung(The University of Texas Health Science Center at San Antonio), Samaneh Kamali(Champions Oncology (United States)), Maria Gaczyńska(The University of Texas at San Antonio Health Science Center), Paweł A. Osmulski(The University of Texas at San Antonio Health Science Center), Paolo Schiavini(Champions Oncology (United States)), Abhishek Pandya(The University of Texas at San Antonio Health Science Center), Vaishnavi Sambandam(National Comprehensive Cancer Network), Christine Gaspard(The University of Texas at San Antonio Health Science Center), Maria Mancini(Champions Oncology (United States)), Lina Song(Union Hospital), Lingtao Jin(The University of Texas Health Science Center at San Antonio), Daniel T. DeArmond(The University of Texas MD Anderson Cancer Center), Meizhen Chen(The University of Texas at San Antonio Health Science Center), Meena Kusi(Deciphera Pharmaceuticals (United States))
Cited by 21
Related Papers
Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing
|Nature Genetics|2013|818
Molecular genetics and cellular events of K-Ras-driven tumorigenesis
|Oncogene|2017|95
Genomic characterization of human papillomavirus-positive and -negative human squamous cell cancer cell lines
|Oncotarget|2017|70
Hedgehog Signaling Blockade Delays Hepatocarcinogenesis Induced by Hepatitis B Virus X Protein
|Cancer Research|2012|66
PDK1 Mediates <i>NOTCH1</i> -Mutated Head and Neck Squamous Carcinoma Vulnerability to Therapeutic PI3K/mTOR Inhibition
|Clinical Cancer Research|2019|51